ACCIUM BIOSCIENCES

Accium BioSciences (Accium) offers pharmaceutical researchers highly sensitive bioanalytics that significantly reduce the time, cost and risk of advancing new drugs from the laboratory to clinical use. Developed at Lawrence Livermore Laboratories, the Accelerator Mass Spectrometer (AMS) that Accium has installed is the only commercial unit in the U.S. Accium is in its development stage and has received an exciting response to their service line. Accium's services have long lead times with impacts that are critical to its customers drug development programs.

THE PEOPLE BEHIND ACCIUM BIOSCIENCES

Dr. Ali Arjomand has been wonderful to work with and we look forward to great contributions from him to our James Tower community. Although we were introduced years ago by a common friend and investment advisor, Rob Martin, this is our first opportunity to work with Loretta Little and Ron Howell of Washington Research Foundations WRF Capital, the lead venture capital firm in Accium. www.acciumbio.com.

IMPLICIT BIOSCIENCE PTY LTD

Implicit BioScience Ltd is a Brisbane-based biotech with offices in our own Jefferson Tower focused on diseases modulated by host immunity. Established relationships with leading international research groups and manufacturers are leveraged to operate Implicit using a virtual development-only business model. Its focus development drug is Oglufanide (IM862), a small molecule dipeptide with potentially wide use for the treatment of infectious disease and cancer.

THE PEOPLE BEHIND IMPLICIT BIOSCIENCE

Abbey was introduced to Implicit BioScience through contacts of the Seattle Science Foundation. The company shares our view of broad reach and networking. The company brings together an international team with skills and experience in all stages of drug development and a history of profitable investor exits. With the company's science led by Ian Frazer (Australian of the Year and co- inventor of Gardasil ), Implicit Bioscience has particularly strong immunology credentials. Established relationships with leading international research groups and manufacturers are leveraged to operate Implicit using a virtual development-only business model. The experienced team of CEO Garry Redlich (Peplin), Chairman Peter Andrews (Biota, Alchemia), Director Dick Haiduck (Abbott, Burrill), VPR D Tim Axtelle (Immunetech, ICOS) and CFO Dan Parry (Accera, Cortech, Synergen, Fujisawa) and Helen Roberts (Agenix, Merck, Bayer) are focused on realistic value creation. http://www.implicitbioscience.com.